RIFM is a non-profit research institute whose purpose is to gather and analyse scientific data, engage in testing and evaluation, distribute information, cooperate with official agencies and to encourage uniform safety standards related to the use of fragrance ingredients. To meet these goals, RIFM takes advantage of recent innovations in risk assessment methodology. The use of BlueScreen™ HC provides accurate, sensitive results that are efficiently integrated into RIFM’s testing cascade and enable more efficient fragrance material evaluation.

BlueScreen™ HC is a highly specific, sensitive human cell based assay used to screen chemicals for their potential to cause damage to DNA: a property known as genotoxicity. Based on technology already used in the pharmaceutical industry, BlueScreen HC is used to provide a rapid assessment of potential hazard across diverse chemical collections in the assessment of new chemicals that are candidates for product development.

The assay evaluates the up-regulation of a key gene’s, GADD45a, response to a chemical that causes damage to, or interferes with, DNA. It measures the luminescence generated from the enzyme Gaussia Luciferase from the marine crustacean Gaussia princeps.

The gene is incorporated into the human TK6 cells used in the assay and linked to GADD45a production.

RIFM and the originators of BlueScreen HC, Gentronix Limited are working closely on the assessment of fragrance materials for use in a wide range of consumer products.

“We found BlueScreen™ HC to be a very useful tool in our fragrance material evaluation process” said RIFM President, Dr. David Wilcox.

Gentronix Commercial Director, Dr. Steve Beasley said: “We have been impressed with the scientific rigor that RIFM brings to the safety evaluation of fragrance materials and their assessment of new technologies such as BlueScreen HC. We look forward to continuing this important collaboration.”

RELATED ARTICLES

Researchers have succeeded in developing a chemical process to absorb infrared light and re-emit it as visible energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light exposure.

A team of scientists has experimentally proved the effectiveness of the formerly suggested "light" method in oncotherapy. In a series of laboratory preclinical tests, the tumor growth stopped in 70% of mice.